Reviews ProHance


No reviews yet.

ProHance Drug Description
ProHance
(gadoteridol) Injection, Solution

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency
(glomerular filtration rate < 30 mL/min/1.73m2), or


acute renal insufficiency of any severity
due to the hepato-renal syndrome or in the perioperative liver transplantation
period.


In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration (See WARNINGS).

DRUG DESCRIPTION
ProHance (Gadoteridol) Injection is a nonionic contrast medium for magnetic resonance imaging (MRI), available as a 0.5M sterile clear colorless to slightly yellow aqueous solution in vials and syringes for intravenous injection.
Gadoteridol is the gadolinium complex of 10-(2-hydroxy-propyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triacetic acid with a molecular weight of 558.7, an empirical formula of C17H29N4O7Gd and has the following structural formula:







Each mL of ProHance contains 279.3 mg gadoteridol, 0.23 mg calteridol calcium, 1.21 mg tromethamine and water for injection. ProHance contains no antimicrobial preservative.
ProHance has a pH of 6.5 to 8.0. Pertinent physicochemical data are noted below:
PARAMETER
Osmolality (mOsmol/kg water) @ 37°C         
   630
Viscosity (cP) @ 20°C             2.0
                       @
37°C             1.3
Specific Gravity @ 25°C           
 1.140
Density (g/mL)@ 25°C             1.137

Octanol: H2Q coefficient-3.68 ± 0.02
ProHance has an osmolality 2.2 times that of plasma (285 mOsmol/kg water) and is hypertonic under conditions of use.
Last reviewed on RxList: 9/25/2007




ProHance Drug Description
ProHance
(gadoteridol) Injection, Solution

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency
(glomerular filtration rate < 30 mL/min/1.73m2), or


acute renal insufficiency of any severity
due to the hepato-renal syndrome or in the perioperative liver transplantation
period.


In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration (See WARNINGS).

DRUG DESCRIPTION
ProHance (Gadoteridol) Injection is a nonionic contrast medium for magnetic resonance imaging (MRI), available as a 0.5M sterile clear colorless to slightly yellow aqueous solution in vials and syringes for intravenous injection.
Gadoteridol is the gadolinium complex of 10-(2-hydroxy-propyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triacetic acid with a molecular weight of 558.7, an empirical formula of C17H29N4O7Gd and has the following structural formula:







Each mL of ProHance contains 279.3 mg gadoteridol, 0.23 mg calteridol calcium, 1.21 mg tromethamine and water for injection. ProHance contains no antimicrobial preservative.
ProHance has a pH of 6.5 to 8.0. Pertinent physicochemical data are noted below:
PARAMETER
Osmolality (mOsmol/kg water) @ 37°C         
   630
Viscosity (cP) @ 20°C             2.0
                       @
37°C             1.3
Specific Gravity @ 25°C           
 1.140
Density (g/mL)@ 25°C             1.137

Octanol: H2Q coefficient-3.68 ± 0.02
ProHance has an osmolality 2.2 times that of plasma (285 mOsmol/kg water) and is hypertonic under conditions of use.
Last reviewed on RxList: 9/25/2007




ProHance Drug Description
ProHance
(gadoteridol) Injection, Solution

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency
(glomerular filtration rate < 30 mL/min/1.73m2), or


acute renal insufficiency of any severity
due to the hepato-renal syndrome or in the perioperative liver transplantation
period.


In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration (See WARNINGS).

DRUG DESCRIPTION
ProHance (Gadoteridol) Injection is a nonionic contrast medium for magnetic resonance imaging (MRI), available as a 0.5M sterile clear colorless to slightly yellow aqueous solution in vials and syringes for intravenous injection.
Gadoteridol is the gadolinium complex of 10-(2-hydroxy-propyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triacetic acid with a molecular weight of 558.7, an empirical formula of C17H29N4O7Gd and has the following structural formula:







Each mL of ProHance contains 279.3 mg gadoteridol, 0.23 mg calteridol calcium, 1.21 mg tromethamine and water for injection. ProHance contains no antimicrobial preservative.
ProHance has a pH of 6.5 to 8.0. Pertinent physicochemical data are noted below:
PARAMETER
Osmolality (mOsmol/kg water) @ 37°C         
   630
Viscosity (cP) @ 20°C             2.0
                       @
37°C             1.3
Specific Gravity @ 25°C           
 1.140
Density (g/mL)@ 25°C             1.137

Octanol: H2Q coefficient-3.68 ± 0.02
ProHance has an osmolality 2.2 times that of plasma (285 mOsmol/kg water) and is hypertonic under conditions of use.
Last reviewed on RxList: 9/25/2007




ProHance Drug Description
ProHance
(gadoteridol) Injection, Solution

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency
(glomerular filtration rate < 30 mL/min/1.73m2), or


acute renal insufficiency of any severity
due to the hepato-renal syndrome or in the perioperative liver transplantation
period.


In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration (See WARNINGS).

DRUG DESCRIPTION
ProHance (Gadoteridol) Injection is a nonionic contrast medium for magnetic resonance imaging (MRI), available as a 0.5M sterile clear colorless to slightly yellow aqueous solution in vials and syringes for intravenous injection.
Gadoteridol is the gadolinium complex of 10-(2-hydroxy-propyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triacetic acid with a molecular weight of 558.7, an empirical formula of C17H29N4O7Gd and has the following structural formula:







Each mL of ProHance contains 279.3 mg gadoteridol, 0.23 mg calteridol calcium, 1.21 mg tromethamine and water for injection. ProHance contains no antimicrobial preservative.
ProHance has a pH of 6.5 to 8.0. Pertinent physicochemical data are noted below:
PARAMETER
Osmolality (mOsmol/kg water) @ 37°C         
   630
Viscosity (cP) @ 20°C             2.0
                       @
37°C             1.3
Specific Gravity @ 25°C           
 1.140
Density (g/mL)@ 25°C             1.137

Octanol: H2Q coefficient-3.68 ± 0.02
ProHance has an osmolality 2.2 times that of plasma (285 mOsmol/kg water) and is hypertonic under conditions of use.
Last reviewed on RxList: 9/25/2007




ProHance Drug Description
ProHance
(gadoteridol) Injection, Solution

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic
fibrosis (NSF) in patients with:

acute or chronic severe renal insufficiency
(glomerular filtration rate < 30 mL/min/1.73m2), or


acute renal insufficiency of any severity
due to the hepato-renal syndrome or in the perioperative liver transplantation
period.


In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle and internal organs. Screen all
patients for renal dysfunction by obtaining a history and/or laboratory tests.
When administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from
the body prior to any readministration (See WARNINGS).

DRUG DESCRIPTION
ProHance (Gadoteridol) Injection is a nonionic contrast medium for magnetic resonance imaging (MRI), available as a 0.5M sterile clear colorless to slightly yellow aqueous solution in vials and syringes for intravenous injection.
Gadoteridol is the gadolinium complex of 10-(2-hydroxy-propyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triacetic acid with a molecular weight of 558.7, an empirical formula of C17H29N4O7Gd and has the following structural formula:







Each mL of ProHance contains 279.3 mg gadoteridol, 0.23 mg calteridol calcium, 1.21 mg tromethamine and water for injection. ProHance contains no antimicrobial preservative.
ProHance has a pH of 6.5 to 8.0. Pertinent physicochemical data are noted below:
PARAMETER
Osmolality (mOsmol/kg water) @ 37°C         
   630
Viscosity (cP) @ 20°C             2.0
                       @
37°C             1.3
Specific Gravity @ 25°C           
 1.140
Density (g/mL)@ 25°C             1.137

Octanol: H2Q coefficient-3.68 ± 0.02
ProHance has an osmolality 2.2 times that of plasma (285 mOsmol/kg water) and is hypertonic under conditions of use.
Last reviewed on RxList: 9/25/2007





Other reviews about ProHance on wordpress

ACR guidence document for safe mr practices:2007
  by turbospinecho
The ACR is Revising their "whitepaper" on safety and it should be out later this week. Here is a small summary of the Contrast safety issues. This was […]


Please take this survey....Thank You
  by turbospinecho
If you took my earlier survery thanks but I had to start this new one, so please retake it. I appreciate your patients with me. If you are […]


Recent news about the Side Effects from Gadolinium are Alarming
  by Donna S
Recent news about the Side Effects from Gadolinium are alarming . Gadolinium is an injectable chemical used during Magnetic Resonance Imagery (MRI) and Magnetic Resonance Angiography (MRA) scans […]


What is Gadolinium?
  by gadolinium
Gadolinium is a chemical used for magnetic resonance imaging (MRI) which helps provide greater contrast between normal tissue and abnormal tissue in the brain and body. The U.S. […]


New Paper Published
  by nicblockley
Field Strength Dependence of R1 and R2* Relaxivities of Human Whole Blood to ProHance, Vasovist, and Deoxyhemoglobin This study has measured the longitudinal and transverse (T2) relaxivity curves for […]


Curriculum Vitae
  by nicblockley
Work Experience 2008 - present        Sir Peter Mansfield Research Fellow Sir Peter Mansfield Magnetic Resonance Centre, University of Nottingham Research Interest: Improving understanding of the BOLD response by modelling the underlying […]


Is Gadolinium in Contrast Dye Safe for MRI Use?
  by wlawgroup1
Gadolinium is a naturally occurring rare-earth metal. This metal has a few properties that are appealing to both the scientific and medical communities. Once such property of Gadolinium […]


Is Gadolinium in Contrast Dye Safe for MRI Use?
  by dsmythe21
Gadolinium is a naturally occurring rare-earth metal. This metal has a few properties that are appealing to both the scientific and medical communities. Once such property of Gadolinium […]


Of Wannabe Entrepreneurs and BTDT Guys - Part II
  by Amit
Note: This is a part of a series covering Start up Saturday's even today (December 12). In the first post of this series, I wrote about two start […]


FDA Warns Of Deadly Side Effect With Imaging Drugs
  by WWJ Newsroom
Federal health regulators are warning doctors that a class of injectable drugs used in MRI medical imaging scans can cause a rare and sometimes fatal condition in patients […]



Other reviews about ProHance on web:

Accurate, FDA approved ProHance information for healthcare professionals and patients - brought to you by Drugs.com. ProHance Official FDA information, side effects and uses.


Learn about the prescription medication ProHance (Gadoteridol Injection Solution), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. ProHance (Gadoteridol Injection Solution) Drug Information: Uses ...


Are You a U.S. Health Care Professional? YES : NO : All users agree that they access and use this site at their own risk. Bracco has not reviewed all of the sites that may be linked ... Bracco Products Portal Site


ProHance® from Bracco Diagnostics, Inc. - Cardiovascular Product Details - Medcompare. Medcompare - The Buyer's Guide for Medical Professionals ProHance® from Bracco Diagnostics, Inc. - Cardiovascular Product ...


Description, information and specification (compound, contrast effect, relaxivity, etc.), further resources and news for the MRI contrast agent/media ProHance from Bracco ... Magnetic Resonance TIP - MRI Database : ProHance


ProHance is a registered trademark of Bracco Diagnostics Inc. 1. Idee JM, Port C, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast ... Bracco Products Portal Site


Chocolate Acai Berry Brownie: 12 x 66g: Made with organic fair trade chocolate and potent antioxidant Acai, deliciousness has never been so good for you! Prohance.ca :: Health Enhancement for Professionals


Prohance and Gadoteridol Information. News and Information on Prohance, Attorneys and Lawyers at LegalView.info Prohance and Gadoteridol - Attorney, Lawsuit, Law Suit, Case ...


We provide business consulting to enhance your profitability. We achieve this by analysing your processes to identify inefficiencies, implementing new streamlined ones, embedding a ... ProHance Limited - Home Page


The dye, Prohance, manufactured by Bracco Diagnostics, has been linked to a disease called NSF/NFD (nephrogenic systemic fibrosis / nephrogenic fibrosing dermopathy). The ... Prohance May Cause NSF/NFD





Featured Reviews

Reviews Bretylium

Bretylium Drug Description DRUG DESCRIPTION BRETYLIUM TOSYLATE INJECTION For Intravenous or Intramuscular Use Bretylium tosylate injection is an antifibrillatory and antiarrhythmic agent; intended for intravenous or intramuscular...
Read More  |  Review This
Reviews Albumin Human, USP, 25% Solution

Buminate 25% Drug Description BUMINATE 25% Albumin (Human), USP, 25% Solution This bottle contains 25 g albumin from venous plasma in buffered diluent and is osmotically equivalent to 500 mL of normal human plasma. It has been stabilized ...
Read More  |  Review This
Reviews Rasagiline

Azilect Drug Description AZILECT® (rasagiline mesylate) Tablets for Oral Use DRUG DESCRIPTION What are the possible side effects of rasagiline (Azilect)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Terazosin Hcl

Hytrin Drug Description HYTRIN® (terazosin hydrochloride) DRUG DESCRIPTION What are the possible side effects of terazosin (Hytrin)? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Reviews Omnitrope

Omnitrope Drug Description Omnitrope® [somatropin (rDNA origin) injection], for subcutaneous use. Omnitrope (somatropin [rDNA origin]) Cartridges and for Injection DRUG DESCRIPTION What are the possible side effects of somatropin? If...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....